Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th

Catabasis Pharmaceuticals, Inc. CATB, a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results.

Conference Call Dial-In Information:

Please specify to the operator that you would like to join the "Catabasis Third Quarter 2019 Results Call."

Interested parties may access a live audio webcast of the conference call via the investors section of the Catabasis website, www.catabasis.com. Please connect to the Catabasis website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005120/en/